On September 8, 2025, Microbot Medical Inc. announced FDA approval for its LIBERTY® Endovascular Robotic System, the first single-use remotely operated robotic system for vascular procedures, paving the way for its commercialization in the U.S. and targeting 2.5 million annual procedures.